Invion Ltd. · ASX:IVX
Invion — Investor Presentation (February 2013)
19 slides from Invion's investor presentation, Feb 25, 2013
Slide 1: Invion Limited – Updated Corporate Presentation (ASX announcement)
ASX / MEDIA ANNOUNCEMENT 25 February 2013 For personal use only INVION LIMITED – UPDATED CORPORATE PRESENTATION Invion Limited (ASX:IVX) is pleased to provide the market with this updated Corporate Presentation. About Invion Limited Invion Limited is a clinical-stage drug development company that ta
Slide 2: Invion Limited (ASX:IVX)
For personal use only Invion Limited (ASX:IVX) Clinical-stage drug development company targeting chronic inflammation William Garner, M.D. February | 2013
Slide 3: Disclaimer
For personal use only Disclaimer This presentation has been prepared by Invion Limited (Invion or the Company) solely for its use at presentations to be made by the Company. The information contained in this presentation is an overview and does not contain all information necessary to make investmen
Slide 4: Experienced leadership team
Experienced leadership team For personal use only William J. Garner MD, CEO > EGB Advisors, Roche, Co-Founder DelMar Pharmaceuticals > Successful corporate founder and executive Mitchell Glass MD, EVP R&D and CMO > 25 year veteran of Pharma (AZ, GSK) and Biotech (AGIX) > Managed more than 40 drug de
Slide 5: Current pipeline
Current pipeline For personal use only Preclinical Phase I Phase II INV102 (oral) Smoking cessation Asthma NIH funded (US$4.4m non-dilutive funding) INV103 (ala-Cpn10) Lupus (SLE) INV102 (inhaled) Chronic bronchitis Cystic fibrosis NCE development Beta-2 adrenergic inverse agonist Academic alliance
Slide 6: INV102 (nadolol)
For personal use only INV102 (nadolol) Existing drug being repurposed for a new target
Slide 7: INV102 (nadolol): overview
INV102 (nadolol): overview > Nadolol is a beta adrenergic inverse agonist (beta blocker) used in the For personal use only treatment of high blood pressure, chest pain and migraine > IVX is repurposing the drug for treatment of chronic obstructive pulmonary disease (COPD) > IVX development strategy
Slide 8: Medical, regulatory and commercial precedent
Medical, regulatory and commercial precedent For personal use only Chronic Heart Failure Chronic Obstructive Pulmonary Disease (CHF) (COPD) Beta-Inverse Agonist Beta-Inverse Agonist e.g. carvedilol e.g. nadolol Beta-Agonist Beta-Agonist (contraindicated (contraindicated for >25 years) for >25 years)
Slide 9: Airway healing: effect of oral INV102
Airway healing: effect of oral INV102 For personal use only Control lung tissue Lung tissue of ‘asthmatic’ mice - Lung tissue of asthmatic mice epithelial cells have been treated with INV102 for 28 converted to mucus-producing days: restored epithelium goblet cells. No effect of alprenolol. Proof of
Slide 10: Chronic cough and failure to quit smoking
Chronic cough and failure to quit smoking* For personal use only 6,000,000 Americans attempt to quit smoking annually 3,000,000 50% fail to quit at 6 months 1,500,000 50% fail to quit early (first 2-4 weeks) 750,000 375,000 Up to 50% of early failures due to 25% of early failures due to cough associ
Slide 11: Oral INV102 development strategy
Oral INV102 development strategy For personal use only Smoking cessation > INV102 can treat underlying cause of chronic cough and mucus secretion which are a major barrier to smoking cessation and cause of peri-operative complications in patients with COPD > Phase II trial in smoking cessation to in
Slide 12: Respiratory Inflammation market $64B+
Respiratory Inflammation market $64B+1. For personal use only > Smoking-Cessation Drug Market worth $2.4B in 20122. > Large COPD /Asthma drug market, valued at ~$34B1. > Advair Diskus ®, approved for asthma and COPD, ($8.1B peak annual sales)3. > Singulair ®, approved for asthma ($5.5B peak annual s
Slide 13: INV103 (ala-Cpn10)
For personal use only INV103 (ala-Cpn10) Modified natural human protein targeting inflammatory disease
Slide 14: INV103 (ala-Cpn10): overview
INV103 (ala-Cpn10): overview For personal use only > Potential new anti-inflammatory biologic therapeutic > Modified version of a naturally occurring human protein, chaperonin10 > Strong patent position covering composition of matter > Novel mechanism: effect on inflammatory markers is different to
Slide 15: Development plan
Development plan For personal use only > Strong pre-clinical data > improved kidney function, resolved cutaneous lupus, reduced renal and circulating levels of inflammatory markers TNF-α and IL-6 > Signals of biological activity in clinical trials to date > Strong safety profile in >250 patients (9
Slide 16: Corporate information
For personal use only Corporate information Listed on the Australian Securities Exchange (ASX:IVX)
Slide 17: Corporate snapshot
Corporate snapshot For personal use only Sector Biotechnology Principal activities Clinical-stage pharmaceutical drug development Intellectual Property assets 2 drug candidates Pipeline status 3 phase II clinical programs ASX code IVX Last trade (12-Feb-13) $0.068 (6.8 cents) Shares on issue 384,531
Slide 18: IVX: potential with mitigated risk
IVX: potential with mitigated risk Management team with significant FDA experience For personal use only > > 5 NDAs > Significant value drivers in 2013 > phase II data > Submission of first NDA possible in less than three years > INV102 (nadolol) in smoking cessation > Strong patent position on both
Slide 19: Invion Limited contact details
For personal use only Invion Limited Managing Director and CEO 2/120 Bluestone Circuit William Garner, M.D. Seventeen Mile Rocks investor@invion.com.au QLD 4073 Australia P: +61 7 3295 0500 Investor and Media Relations F: +61 7 3295 0599 Buchan Consulting W: www.invion.com.au rwilson@buchanwe.com.au